Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Gepotidacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Blujepa (Gepotidacin) FDA-Approved for Uncomplicated Urinary Tract Infections
Details : Blujepa (gepotidacin) is the first in a new class of oral antibiotics which inhibits topoisomerase II/IV. It is approved for the treatment of uncomplicated urinary tract infections.
Product Name : Blujepa
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 25, 2025
Lead Product(s) : Gepotidacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gepotidacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EAGLE-1 Phase III Data Show Gepotidacin As New Oral Treatment for Gonorrhoea
Details : GSK 2140944 (gepotidacin) is a potential first-in-class oral antibiotic which inhibits bacterial DNA replication, with a novel mechanism of action for uncomplicated urogenital gonorrhoea.
Product Name : GSK 2140944
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 17, 2024
Lead Product(s) : Gepotidacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gepotidacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GSK Reports Positive Results from EAGLE-1 Trial for Gepotidacin
Details : GSK 2140944 (gepotidacin) is an investigational bactericidal antibiotic inhibiting bacterial DNA replication by a novel mechanism, evaluated for treating uncomplicated urogenital gonorrhea.
Product Name : GSK 2140944
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 26, 2024
Lead Product(s) : Gepotidacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gepotidacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GSK 2140944 (gepotidacin) is an investigational bactericidal that inhibits bacterial DNA replication by a novel mechanism of action and binding site and provides well-balanced inhibition of two different Type II topoisomerase enzymes.
Product Name : GSK 2140944
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 15, 2023
Lead Product(s) : Gepotidacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gepotidacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The EAGLE-2 and EAGLE-3 trials met primary efficacy endpoint of combined clinical and microbiological resolution following treatment at the Test-Of-Cure visit for gepotidacin (GSK 2140944) v/s nitrofurantoin in patients with uUTI and a uropathogen sensit...
Product Name : GSK 2140944
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : Gepotidacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable